Approved indications
Tudorza Pressair (aclidinium bromide) is FDA-approved as a maintenance bronchodilator treatment for airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and is not intended for relief of acute bronchospasm or for the treatment of asthma.

Off-label uses
Off-label use of aclidinium is limited; it is occasionally considered when clinicians need an alternative long-acting muscarinic antagonist for COPD maintenance, but it is not commonly used or well established for other conditions, and evidence for non-COPD uses remains sparse.

Efficacy expectations
Some people notice easier breathing and reduced symptoms within the first few doses, with more consistent improvement over several days to a few weeks of regular use. Clinical trials show improved lung function (such as higher FEV₁), fewer daily symptoms, and reduced need for rescue inhalers compared with placebo. Compared with other LAMA inhalers for COPD (such as tiotropium or umeclidinium), Tudorza Pressair provides similar maintenance benefits when taken correctly, so choice often depends on inhaler preference, dosing schedule, insurance coverage, and overall treatment plan.

Typical dosing and how to take it
For adults with COPD, the usual dose is one inhalation (400 mcg) twice daily by mouth through the Tudorza Pressair device, ideally about 12 hours apart, at the same times each day. It can be taken with or without food. To use, breathe out fully away from the inhaler, seal lips around the mouthpiece, then inhale quickly and deeply until a click is heard, continuing to inhale to draw the medicine into the lungs, then hold the breath briefly before exhaling.

Special dosing instructions
Do not exceed the prescribed number of inhalations, and do not use Tudorza Pressair as a rescue inhaler for sudden symptoms. Check the dose indicator before use, and ensure the control window and counter move as described in the device instructions; if the dose does not appear to load or release properly, repeat the steps once, and contact a pharmacist or clinician if problems continue. No dosage adjustment is typically required based solely on mild to moderate kidney or liver impairment, but overall COPD severity and other conditions may affect the treatment plan.

Missed doses
If a dose is missed, take it as soon as you remember, unless it is almost time for the next scheduled dose; in that case, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed dose.

Overdose
In suspected overdose, people may experience marked anticholinergic symptoms such as severe dry mouth, blurred vision, eye pain, difficulty urinating, or a fast or irregular heartbeat, along with worsening breathing. Seek emergency medical care or contact a poison control center immediately if too many doses have been taken or if severe symptoms occur.

Common side effects
Common side effects (generally mild to moderate) can include headache, cough, nasopharyngitis or sore throat, sinus infection, diarrhea, nausea, and muscle spasms. Dry mouth is possible but tends to be less frequent than with some other anticholinergic medicines. These effects often appear in the first days to weeks of treatment and may lessen over time.

Serious or rare adverse effects
Serious reactions are uncommon but require immediate medical attention and include: paradoxical bronchospasm (sudden worsening of wheezing or shortness of breath after inhalation), severe allergic reactions (rash, hives, swelling of face, lips, tongue, or throat, or difficulty breathing), new or worsening narrow-angle glaucoma (eye pain, blurred vision, seeing halos or colored images, red eyes), and urinary retention (painful or difficult urination, feeling unable to empty the bladder). Very high exposure or overdose can cause pronounced anticholinergic effects such as fast heartbeat, severe dry mouth, or confusion.

Warnings and precautions
Tudorza Pressair should not be used to treat sudden breathing problems; a rescue inhaler (such as a short-acting beta-agonist) is needed for acute symptoms. Use with caution in people with narrow-angle glaucoma, urinary retention, enlarged prostate, or bladder outlet obstruction, as anticholinergic effects can worsen these conditions. It is not established for use in children. In pregnancy or while breastfeeding, safety data are limited; clinicians weigh potential benefits for the parent against possible risks to the fetus or infant, but systemic exposure from inhaled aclidinium is low.

Comparative safety
Within the class of long-acting muscarinic antagonist (LAMA) inhalers, Tudorza Pressair has a safety profile generally similar to other agents, with primarily localized respiratory and mild anticholinergic side effects and a low rate of serious adverse events when used as directed.

Reporting side effects and safety updates
Patients should tell their healthcare provider about any bothersome or unexpected symptoms. Side effects can be reported directly to the FDA through the MedWatch program by phone or online, which helps track rare or emerging safety issues. Up-to-date safety information is available from the prescribing information, pharmacists, and regulatory safety communications.

Drug and supplement interactions
Tudorza Pressair has relatively low systemic absorption, so major drug–drug interactions are uncommon, but using it with other anticholinergic medicines (such as some bladder, Parkinson’s, or other inhaled bronchodilator medications) can increase anticholinergic side effects like dry mouth, blurred vision, constipation, or urinary retention. There are no well-known direct interactions with most common blood pressure medicines, cholesterol drugs, or diabetes medicines, and no specific food interactions have been identified. Alcohol does not directly interact with aclidinium but can worsen dizziness or overall COPD control in some people.

Diagnostic procedures and other precautions
Tudorza Pressair does not usually interfere with imaging tests or most diagnostic procedures. However, because it is an anticholinergic bronchodilator, clinicians may consider holding or documenting its use before certain pulmonary function tests so results are interpreted correctly.

Conditions requiring caution
Use with caution in people with narrow-angle glaucoma, urinary retention, enlarged prostate, or bladder outlet obstruction, as symptoms of these conditions can worsen. Patients with severe heart disease should discuss all inhaled COPD medicines with their clinician, since COPD itself and some inhaled therapies can affect heart symptoms. It is not routinely used in children or adolescents because safety and effectiveness in this group have not been established.

Monitoring needs
Routine monitoring includes checking COPD symptoms, rescue inhaler use, and periodic lung function tests to assess control. Patients at risk for glaucoma or urinary retention should be monitored for eye pain or vision changes and for urinary difficulties. Regular review of all prescription drugs, over-the-counter medicines, and supplements helps reduce the risk of overlapping anticholinergic effects.

Q: Is Tudorza Pressair a rescue inhaler or a maintenance inhaler?
A: Tudorza Pressair is a maintenance inhaler used every day to help keep COPD symptoms under control; it does not work fast enough to relieve sudden breathing problems, so a separate quick-relief (rescue) inhaler is still needed.

Q: How quickly will I notice improvement after starting Tudorza Pressair?
A: Some people feel easier breathing within the first few doses, but the full benefit usually develops over several days to a few weeks of taking it twice daily as prescribed.

Q: Can Tudorza Pressair be used for asthma?
A: No, Tudorza Pressair is not approved for asthma and is intended only for maintenance treatment of COPD; asthma requires a different treatment plan that often includes inhaled corticosteroids and other specific medicines.

Q: Is there a steroid in Tudorza Pressair?
A: No, Tudorza Pressair does not contain a steroid; it contains aclidinium, a long-acting muscarinic antagonist (LAMA) that relaxes airway muscles but does not have corticosteroid effects.

Q: What should I do if my breathing suddenly gets worse while using Tudorza Pressair?
A: Use your prescribed rescue inhaler right away for quick relief, and seek urgent medical care if symptoms are severe, do not improve, or are accompanied by chest pain, confusion, or bluish lips or fingernails; also contact your clinician soon to review your COPD treatment plan.

Q: Can I use Tudorza Pressair with my other COPD inhalers?
A: Tudorza Pressair is often used together with other types of COPD medicines, such as long-acting beta-agonists and inhaled corticosteroids, but it should not be combined with other LAMA inhalers or unnecessary anticholinergic drugs without your clinician’s guidance.

Storage
Store Tudorza Pressair at room temperature, generally around 68°F to 77°F (20°C to 25°C), in a dry place away from excessive heat, cold, or moisture. Keep the inhaler in its sealed pouch until first use, and close the protective cap after each use to keep the device clean and dry.

In-use shelf life and discarding
Check the dose counter regularly and discard the inhaler when it shows zero doses or when it has been in use for the period specified on the label (often about 45 days after opening the pouch), even if doses remain. Do not use the inhaler after the expiration date printed on the packaging.

Disposal
Keep the inhaler out of reach of children and pets, and do not disassemble, puncture, or burn it. When finished, discard it with household trash unless local regulations recommend returning inhalers or medications to a pharmacy take-back program.